Neurocrine Biosciences (NBIX) fundamentals: P/E, valuation, undervalued?
Neurocrine Biosciences · Health Care · ref. ETF XLV · price $135.13
In short — Neurocrine Biosciences trades at 19.8× earnings (P/E), 11.2× forward, with a net margin of 20.9 % and revenue growth of +40 %. Read: Cheap for the growth (P/E 11 for ~31% growth (PEG 0.4)).
Is Neurocrine Biosciences stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$135.13-1.5% over range
Oct 14, 25low $123.1 · high $185.5Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
89% recommend buying · 18 analysts
Valuation : Cheap for the growth — P/E 11 for ~31% growth (PEG 0.4)
Valuation
19.8
P/E (price/earnings)
11.2
Forward P/E
0.64
PEG
3.7
Price/book (P/B)
$13.7B
Market cap
6.82
EPS
Profitability & growth
20.9 %
Net margin
+40 %
Revenue growth
+31 %
Earnings growth
$462M
Total debt
Neurocrine Biosciences income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $1.5B | $155M | 10.4 % |
| 2023 | $1.9B | $250M | 13.2 % |
| 2024 | $2.4B | $341M | 14.5 % |
| 2025 | $2.9B | $479M | 16.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Neurocrine Biosciences's P/E and is the stock undervalued? What's a good P/E?
Neurocrine Biosciences's P/E is 19.8 (forward 11.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Neurocrine Biosciences profitable?
Neurocrine Biosciences has a net margin of 20.9 % (EPS 6.82). The company is profitable.
Is NBIX stock expensive?
Our read: "Cheap for the growth" — P/E 11 for ~31% growth (PEG 0.4). Cross-check with growth and sector.
💬 A question about Neurocrine Biosciences? The JPI assistant answers using our backtest data.
Keep exploring Neurocrine Biosciences